Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms TAXT-XRT
- 24 Feb 2017 Status changed from active, no longer recruiting to completed.
- 19 Sep 2005 New trial record.